Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial
Version 2 2024-06-04, 04:31Version 2 2024-06-04, 04:31
Version 1 2018-05-31, 09:01Version 1 2018-05-31, 09:01
journal contribution
posted on 2024-06-04, 04:31authored byGM Duchesne, HH Woo, M King, Steve BoweSteve Bowe, MR Stockler, A Ames, C D'Este, M Frydenberg, A Loblaw, S Malone, J Millar, KH Tai, S Turner
Health-related quality of life for immediate versus delayed androgen-deprivation therapy in patients with asymptomatic, non-curable prostate cancer (TROG 03.06 and VCOG PR 01-03 [TOAD]): a randomised, multicentre, non-blinded, phase 3 trial